Not Specified

About Asceneuron

Asceneuron is a clinical-stage biotech based in Lausanne, Switzerland, pioneering oral small molecule therapies that target tau protein pathology for neurodegenerative diseases. The company is advancing a pipeline focused on Alzheimer's, Parkinson's, and rare tauopathies, backed by a strong syndicate of leading life science investors. A recent $100 million Series C financing provides significant capital to advance its lead programs through clinical development. Asceneuron represents a focused player in the challenging but high-potential neurodegenerative disease space.

About Asceneuron

Asceneuron is a clinical-stage biotech based in Lausanne, Switzerland, pioneering oral small molecule therapies that target tau protein pathology for neurodegenerative diseases. The company is advancing a pipeline focused on Alzheimer's, Parkinson's, and rare tauopathies, backed by a strong syndicate of leading life science investors. A recent $100 million Series C financing provides significant capital to advance its lead programs through clinical development. Asceneuron represents a focused player in the challenging but high-potential neurodegenerative disease space.

About Asceneuron

Asceneuron is a clinical-stage biotech based in Lausanne, Switzerland, pioneering oral small molecule therapies that target tau protein pathology for neurodegenerative diseases. The company is advancing a pipeline focused on Alzheimer's, Parkinson's, and rare tauopathies, backed by a strong syndicate of leading life science investors. A recent $100 million Series C financing provides significant capital to advance its lead programs through clinical development. Asceneuron represents a focused player in the challenging but high-potential neurodegenerative disease space.

About New Amsterdam Sciences

New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.

About New Amsterdam Sciences

New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.

About New Amsterdam Sciences

New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.

About New Amsterdam Sciences

New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.

About New Amsterdam Sciences

New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.

About New Amsterdam Sciences

New Amsterdam Sciences is a private, preclinical-stage biotech focused on an anti-inflammatory platform targeting reactive oxygen species (ROS)-driven inflammation. Its pipeline is broad and early-stage, spanning human therapeutics for rheumatoid arthritis, COVID-19, influenza, and neurodegenerative diseases like Progressive Supranuclear Palsy, as well as programs in animal health and radiomitigation. The company appears to be pre-revenue, relying on private investment to advance its research, and faces significant execution risk due to its early technology stage and wide-ranging pipeline focus.

Therapeutic Areas

Other Alzheimer's Disease Drugs